Cellular Biomedicine Group Announces Enrollment Milestone for Phase I Clinical Trial for Liver Cancer

To date the trial has had no Severe Adverse Effect reported. The Phase I clinical trial for TC-DC therapy for HCC, registered with NIH under number NCT01828762 is an open label clinical trial conducted with 's PLA 85 Hospital, one of the Liver Disease Centers of People's Liberation Army.

http://www.prnewswire.com/news-releases/cellular-biomedicine-group-announces-enrollment-milestone-for-phase-i-clinical-trial-for-liver-cancer-208463611.html